Tofacitinib (Xeljanz, Pfizer), in combination with methotrexate, is indicated 'for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic drug (DMARD) therapy'.
The recommended dose of tofacitinib is 5 mg taken orally twice daily.
No dose adjustment is needed when tofacitinib is used with methotrexate. Treatment should be interrupted if a patient develops a serious infection until the infection is controlled.
The list price of a 56‑tablet pack of 5 mg tofacitinib is £690.03 (excluding VAT; BNF online [accessed July 2018]).
The company has a commercial arrangement. This makes tofacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.